DelveInsight, a leading market research and consulting firm, announces the release of its latest report, “Parkinson’s Disease Psychosis Market Insights, Epidemiology, and Market Forecast–2036.” The report provides an in-depth understanding of Parkinson’s Disease Psychosis, including historical and forecasted epidemiology, current treatment practices, emerging therapies, market trends, market size, market share, and competitive landscape across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.
Key Takeaways from the Parkinson’s Disease Psychosis Market
The Parkinson’s Disease Psychosis market size across the 7MM is expected to grow steadily during the forecast period 2022–2036.
The total Parkinson’s Disease Psychosis market size in the 7MM was approximately USD 738 million in 2025 and is projected to reach nearly USD 1.7 billion by 2036.
In 2025, the total diagnosed prevalent cases of Parkinson’s Disease Psychosis across the 7MM were approximately 900 thousand cases and are expected to increase through 2036.
The United States accounted for nearly 50% of the total diagnosed prevalent cases of Parkinson’s Disease Psychosis in the 7MM in 2025.
EU4 and the United Kingdom collectively represented approximately 40% of the total diagnosed prevalent cases, while Japan accounted for nearly 10%.
Germany accounted for the highest diagnosed prevalent Parkinson’s Disease Psychosis cases among EU4 and the UK, with approximately 130 thousand cases in 2025.
Japan reported approximately 75 thousand diagnosed prevalent Parkinson’s Disease Psychosis cases in 2025, with patient numbers anticipated to increase throughout the forecast period.
Leading Parkinson’s Disease Psychosis companies include Acadia Pharmaceuticals and Ovid Therapeutics, among others.
Key Parkinson’s Disease Psychosis therapies include NUPLAZID (pimavanserin), Quetiapine, Clozapine, and emerging candidate OV4071.
Keen to know more about the market? Request our sample page at Parkinson’s Disease Psychosis Market Report.
Key Factors Driving the Parkinson’s Disease Psychosis MarketIncreasing Prevalence of Parkinson’s Disease
The growing aging population worldwide is contributing to a rising prevalence of Parkinson’s disease. As disease duration increases, a larger proportion of patients develop psychosis-related symptoms, creating significant demand for effective treatment options.
Rising Recognition of Non-Motor Symptoms
Healthcare providers are increasingly recognizing Parkinson’s Disease Psychosis as a major non-motor complication associated with reduced quality of life, increased healthcare utilization, and greater caregiver burden. Improved diagnosis is expected to support market growth.
Growing Adoption of Targeted Therapies
The availability of NUPLAZID, the only FDA-approved therapy specifically indicated for hallucinations and delusions associated with Parkinson’s Disease Psychosis, has significantly improved treatment standards and increased awareness of disease-specific therapeutic approaches.
Emergence of Novel Pipeline Therapies
Emerging therapies targeting new neurological pathways are expected to provide additional treatment options. The development of OV4071 and other innovative therapies could potentially address unmet needs related to efficacy, safety, and tolerability.
Parkinson’s Disease Psychosis Competitive Landscape
Several Parkinson’s Disease Psychosis therapies are currently used in clinical practice, including NUPLAZID (pimavanserin), Quetiapine, and Clozapine. NUPLAZID remains the only FDA-approved therapy specifically indicated for hallucinations and delusions associated with Parkinson’s Disease Psychosis and continues to dominate the treatment market. Quetiapine and Clozapine are frequently used off-label based on physician preference and patient-specific considerations.
The emerging Parkinson’s Disease Psychosis pipeline includes OV4071 (Ovid Therapeutics), an oral direct KCC2 activator planned for clinical evaluation in psychosis associated with Parkinson’s disease and Lewy body dementia. The therapy aims to address significant unmet needs in neuropsychiatric symptom management and may provide a differentiated treatment approach.
Discover more about therapies set to grab major Parkinson’s Disease Psychosis market share @ Parkinson’s Disease Psychosis Treatment Landscape.
Recent Developments in the Parkinson’s Disease Psychosis Market
In September 2023, Acadia Pharmaceuticals announced that the US FDA updated the NUPLAZID label to clarify its use in treating hallucinations and delusions associated with Parkinson’s Disease Psychosis without introducing new safety findings.
Ovid Therapeutics continues advancing OV4071, an oral direct KCC2 activator, for psychosis associated with Parkinson’s disease and Lewy body dementia.
Ongoing research efforts continue to evaluate novel approaches to managing psychosis while minimizing deterioration of motor function in Parkinson’s disease patients.
What is Parkinson’s Disease Psychosis?
Parkinson’s Disease Psychosis (PDP) is a serious neuropsychiatric complication of Parkinson’s disease characterized by hallucinations, delusions, illusions, and other psychotic symptoms. Visual hallucinations are the most common manifestation, although patients may also experience auditory hallucinations, depression, anxiety, and cognitive impairment. PDP is associated with increased morbidity, reduced quality of life, longer nursing home stays, and greater caregiver burden.
Parkinson’s Disease Psychosis Epidemiology Segmentation
The Parkinson’s Disease Psychosis epidemiology section provides insights into historical and forecasted patient populations across the 7MM and includes:
Total Diagnosed Prevalent Cases of Parkinson’s Disease
Total Diagnosed Prevalent Cases of Parkinson’s Disease Psychosis
Country-specific Diagnosed Prevalent Cases of Parkinson’s Disease Psychosis
Age-related Disease Burden Trends
Forecasted Epidemiology Trends Across the 7MM
Scope of the Parkinson’s Disease Psychosis Market Report
Therapeutic Assessment: Current and Emerging Parkinson’s Disease Psychosis Therapies
Parkinson’s Disease Psychosis Market Dynamics: Market Drivers, Barriers, and Opportunities
Key Companies: Acadia Pharmaceuticals, Ovid Therapeutics, and others
Key Therapies: NUPLAZID (Pimavanserin), Quetiapine, Clozapine, OV4071, and others
Competitive Intelligence Analysis: SWOT Analysis and Market Entry Strategies
Market Size, Market Share, Industry Trends, and Forecast Analysis
KOL Perspectives, Analyst Views, Market Access, and Reimbursement Assessment
To know more about Parkinson’s Disease Psychosis companies working in the treatment market, visit @ Parkinson’s Disease Psychosis Clinical Trials and Therapeutic AssessmentTable of Contents
Parkinson’s Disease Psychosis Market Report Introduction
Executive Summary for Parkinson’s Disease Psychosis
SWOT Analysis of Parkinson’s Disease Psychosis
Parkinson’s Disease Psychosis Patient Share (%) Overview at a Glance
Parkinson’s Disease Psychosis Market Overview at a Glance
Parkinson’s Disease Psychosis Disease Background and Overview
Parkinson’s Disease Psychosis Epidemiology and Patient Population
Country-Specific Patient Population of Parkinson’s Disease Psychosis
Parkinson’s Disease Psychosis Current Treatment and Medical Practices
Parkinson’s Disease Psychosis Unmet Needs
Parkinson’s Disease Psychosis Emerging Therapies
Parkinson’s Disease Psychosis Market Outlook
Country-Wise Parkinson’s Disease Psychosis Market Analysis (2022–2036)
Parkinson’s Disease Psychosis Market Access and Reimbursement
Parkinson’s Disease Psychosis Market Drivers
Parkinson’s Disease Psychosis Market Barriers
Parkinson’s Disease Psychosis Appendix
Parkinson’s Disease Psychosis Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through its subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
